Variant alleles of SLC22A16 are associated with response and levels of toxicity caused by doxorubicin and cyclophosphamide therapy in the treatment of breast cancer which is consistent with the fact that doxorubicin is a substrate this transporter (Bray et al., 2010). The gene discussed is SLC22A16; the disease is breast carcinoma.